The company’s Q4 revenue jumped 52.3% (excl. However JD Health continues to deliver rapid growth. It sells pharmaceutical and healthcare products, provides online healthcare services like medical consultations, and manages its supply chain.įears over China’s economic slowdown and regulatory crackdowns have weighed on the stock over the past year. JD Health operates China’s largest online pharmacy and third-largest online medical platform. But the company is a hidden gem trading at a rock-bottom valuation, after the shellacking Chinese equities endured last year. investors are unfamiliar with this Chinese online retailer, JD Health (OTCMKTS: JDHIF). Additionally, the consensus analyst price target at $45 implies 39% upside. Value investors building a position at current levels will be rewarded handsomely over the next decade. The stock trades at just 10-times forward earnings, while paying a tasty 5% dividend yield. While near-term results will remain pressured as high-margin Covid-related products roll off, Pfizer’s pipeline investments position it well for the long-run. Plus, the planned $43 billion takeover of Seagen (NASDAQ: SGEN) will further expand Pfizer’s presence in oncology. The company leveraged its robust pandemic profits and balance sheet to acquire many other companies to reinforce growth during that period. Pfizer possesses tremendous financial strength, with over $26 billion in 2022 in cash flow. The company also reaffirmed guidance for 6-8% operational revenue growth this year, excluding its vaccine portfolio. But notably, sales from non-COVID products climbed 5% operationally. Recent Q2 results showed the early impact of waning pandemic demand, with revenues sliding 54% year-over-year. The company has an industry-leading drug pipeline and plans to launch up to 19 new products over the next 18-months. While the company’s vaccine and therapeutic sales boom fueled by Covid-19 have faded, Pfizer’s underlying business remains rock solid. Pfizer (NASDAQ: PFE) stock is down nearly 45% from its early 2022 highs. With that said, here are three pharma stocks to look into right now. So, spreading bets across multiple names is prudent. ![]() Of course, drug development is inherently risky, with no guarantees of clinical trial victories. These are businesses with efficient operations, robust cash flows, and management teams with a track record of success. The pharma industry is a complex one, so you’d only want to own the highest quality companies with the most compelling pipelines. These are pharma stocks that could potentially double your money over the next 12-24 months. ![]() Rather than chasing risky biotech startups, I’ll be focusing on proven industry leaders with strong growth drivers and upside catalysts on the horizon. Right now, the healthcare sector appears to be resilient, with several pharma stocks poised for massive gains ahead. I believe such pharma stocks will deliver outsized returns when sentiment improves. ![]() While some Pharma sub-sectors such as vaccine stocks have been hit especially hard amidst the recent volatility, the future still remains bright for pharma companies with a diverse pipeline. But seasoned investors know the ups and downs are part of the natural ebb and flow of the market, and that patience and discipline are rewarded in the long-run. The pharmaceuticals market has taken a bit of a breather in recent weeks after an exhilarating rally earlier this year.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |